(3Z,6Z)-3-[(5-叔丁基-1H-咪唑-4-基)亚甲基]-6-(苯亚甲基)-2,5-哌嗪二酮

Plinabulin (NPI-2358)是一种VDA,能结合微管蛋白的秋水仙碱结合位点,IC50为9.8-18 nM。

信号通路 >> 细胞周期/DNA损伤 >> 微管/微管蛋白

信号通路 >> 细胞骨架 >> 微管/微管蛋白

研究领域 >> 癌症

[1]. Nicholson B et al. NPI-2358 is a tubulin-depolymerizing agent: in-vitro evidence for activity as a tumor vascular-disrupting agent. Anticancer Drugs. 2006 Jan;17(1):25-31.

[2]. Monica M. Mita et al. Phase 1 First-in-Human Trial of the Vascular Disrupting Agent Plinabulin (NPI-2358) in Patients with Solid Tumors or Lymphomas Clin Cancer Res December 1, 2010 16; 5892

[3]. Yakushiji F, Tanaka H, Muguruma K, Iwahashi T, Yamazaki Y, Hayashi Y.,Prodrug study of plinabulin using a click strategy focused on the effects of a replaceable water-solubilizing moiety.,Chem Pharm Bull (Tokyo). 2012;60(7):877-81.

[4]. Yamazaki Y, Sumikura M, Masuda Y, Hayashi Y, Yasui H, Kiso Y, Chinen T, Usui T, Yakushiji F, Potts B, Neuteboom S, Palladino M, Lloyd GK, Hayashi Y.,Synthesis and structure-activity relationships of benzophenone-bearing diketopiperazine-type anti-microtubule agents.,Bioorg Med Chem. 2012 Jul 15;20(14):4279-89. Epub 2012 Jun 4.

[5]. Bertelsen LB, Shen YY, Nielsen T, St?dkilde-J?rgensen H, Lloyd GK, Siemann DW, Horsman MR.,Vascular effects of plinabulin (NPI-2358) and the influence on tumour response when given alone or combined with radiation.Int J Radiat Biol. 2011 Nov;87(11):1126-34.

诺考达唑 | 一甲基澳瑞他汀E | VcMMAE | Mertansine(DM1化合物) | 甲磺酸艾瑞布林 | 埃博霉素 | 酒石酸长春瑞滨 | 埃博霉素B | McMMAF | MMAF盐酸盐 | 伊沙匹隆 | N,BETA,BETA-三甲基-L-苯基丙氨酰基-N-[(1S,2E)-3-羧基-1-(1-甲基乙基)-2-丁烯基]-N,3-二甲基-L-缬氨酰胺 | 雌莫司汀磷酸钠 | 安丝菌素P3 | 康普瑞汀磷酸二钠